肺癌药物靶点基因突变优势人群分析数据

肺癌药物靶点基因突变优势人群分析数据通过对肺癌应用药物靶点基因突变在性别、年龄段、地区的分布数据分组分析及对比分析，筛选出突变优势人群，通过数据更新可实现历年数据变化监控。可应用于肺癌靶向药物相关学术研究，肺癌靶向药物新药研发中临床试验入组以及药物推广方案制定，临床中诊疗方案制定等场景。1.数据采集：采集肺癌患者性别、年龄、地区等信息（不涉及能够识别自然人个人身份的信息）；
2.基因检测：通过高通量测序技术检测患者样本的基因突变情况；
3.数据分类：按照性别、年龄、地区（省份）三类指标，将数据进行分组。根据患者性别分为男性、女性；根据年龄将患者分成不同年龄段人群；根据地区将患者分成不同地区（省份）人群；
4.分组分析：
指标一：肺癌药物靶点基因突变在特定性别患者中的突变比例=该靶点基因突变的该性别患者数/进行该靶点基因突变检测的该性别患者总数；
指标二：肺癌药物靶点基因突变在特定年龄段患者中的突变比例=该靶点基因突变的该年龄段患者数/进行该靶点基因突变检测的该年龄段患者总数；
指标三：肺癌药物靶点基因突变在特定地区（省份）患者中的突变比例=该靶点基因突变的该地区（省份）患者数/进行该靶点基因突变检测的该地区（省份）患者总数；
5.对比分析：对上述数据进行综合分析，分别提取出肺癌药物各靶点基因突变在三类指标中的最大值，即为该靶点基因突变优势人群，通过数据更新亦可实现优势人群变化监控。

This dataset, aimed at analyzing dominant populations carrying gene mutations of lung cancer drug targets, screens out such dominant populations by performing grouped and comparative analyses on the distribution data of such mutations across gender, age groups and regions. Regular data updates enable monitoring of annual changes in the dataset. It can be applied to scenarios including academic research on lung cancer targeted drugs, clinical trial enrollment during the R&D of new lung cancer targeted drugs, development of drug promotion strategies, and formulation of clinical diagnosis and treatment plans.
1. Data Collection: Collect information of lung cancer patients including gender, age and region, without any personally identifiable information (PII).
2. Genetic Testing: Detect gene mutations in patient samples using high-throughput sequencing technology.
3. Data Classification: Group the dataset based on three indicators: gender, age and region (province). Specifically, patients are categorized into male and female groups by gender, divided into different age groups by age, and grouped into different regional (provincial) groups by their residential region.
4. Grouped Analysis:
Indicator 1: Mutation proportion of lung cancer drug target gene mutations in patients of a specific gender = (Number of patients with the target gene mutation in this gender) / (Total number of patients who underwent gene mutation testing for this target in this gender);
Indicator 2: Mutation proportion of lung cancer drug target gene mutations in patients of a specific age group = (Number of patients with the target gene mutation in this age group) / (Total number of patients who underwent gene mutation testing for this target in this age group);
Indicator 3: Mutation proportion of lung cancer drug target gene mutations in patients of a specific region (province) = (Number of patients with the target gene mutation in this region) / (Total number of patients who underwent gene mutation testing for this target in this region);
5. Comparative Analysis: Conduct comprehensive analysis on the above data, extract the maximum mutation proportion of each lung cancer drug target gene mutation across the three indicators. The corresponding patient group is the dominant population carrying this target gene mutation. Regular data updates also allow monitoring of changes in these dominant populations over time.

搜集汇总

数据集介绍

特点

该数据集包含290条肺癌患者基因突变数据，每日更新，用于分析肺癌药物靶点基因突变在性别、年龄和地区的分布，支持靶向药物研发和临床诊疗。